At a glance
- Originator Roche
- Class Antiplatelets; Small molecules; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis; Unstable angina pectoris
Most Recent Events
- 16 Aug 2002 No development reported - Preclinical for Thrombosis in Switzerland (unspecified route)
- 16 Aug 2002 No development reported - Preclinical for Unstable angina pectoris in Switzerland (unspecified route)
- 08 Sep 1998 A preclinical study has been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics sections